Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report)'s stock price fell 12.4% during mid-day trading on Friday. The stock traded as low as $72.00 and last traded at $70.6430. Approximately 507,381 shares were traded during trading, a decline of 63% from the average session volume of 1,367,198 shares. The stock had previously closed at $80.65.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on ABVX. Wall Street Zen lowered Abivax from a "hold" rating to a "sell" rating in a research note on Saturday, September 26th. Barclays reissued an "overweight" rating and set a $148.00 price objective on shares of Abivax in a research report on Tuesday, September 22nd. Wedbush lowered their price target on shares of Abivax from $118.00 to $96.00 and set a "neutral" rating for the company in a research report on Wednesday, October 21st. Morgan Stanley reaffirmed an "overweight" rating and set a $180.00 target price on shares of Abivax in a research note on Friday, July 24th. Finally, Piper Sandler reaffirmed an "overweight" rating on shares of Abivax in a research report on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $155.00.
Get Our Latest Research Report on Abivax
Abivax Price Performance
The company has a market cap of $6.43 billion, a P/E ratio of -12.15 and a beta of 1.36. The stock's 50-day moving average is $92.07 and its two-hundred day moving average is $111.93.
Abivax (NASDAQ:ABVX - Get Free Report) last announced its earnings results on Monday, September 21st. The company reported ($1.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.79). The business had revenue of $1.37 million for the quarter, compared to analyst estimates of $0.80 million. On average, analysts predict that Abivax SA Sponsored ADR will post -4.14 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Eversept Partners LP increased its position in shares of Abivax by 42.0% during the 1st quarter. Eversept Partners LP now owns 934,423 shares of the company's stock valued at $104,048,000 after purchasing an additional 276,589 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Abivax by 31.6% during the 1st quarter. Janus Henderson Group PLC now owns 878,829 shares of the company's stock worth $98,007,000 after acquiring an additional 211,068 shares during the last quarter. Logos Global Management LP bought a new stake in shares of Abivax during the 3rd quarter valued at $86,147,000. Bank of America Corp DE grew its position in shares of Abivax by 40.9% during the 1st quarter. Bank of America Corp DE now owns 735,729 shares of the company's stock valued at $81,923,000 after acquiring an additional 213,440 shares during the period. Finally, Aberdeen Group plc grew its position in shares of Abivax by 45.8% during the 3rd quarter. Aberdeen Group plc now owns 761,016 shares of the company's stock valued at $75,356,000 after acquiring an additional 238,991 shares during the period. 47.91% of the stock is owned by hedge funds and other institutional investors.
About Abivax
(
Get Free Report)
Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body's immune response. The company's lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation. Founded in 2013, Abivax conducts clinical development internationally.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abivax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.
While Abivax currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.